drugset / Trial / NCT00362505

Safety and Antiviral Activity of Clevudine in Patients Who Have Completed the L-FMAU-301 or L-FMAU-302 Trials

NCT00362505

Phase 3 Terminated Bukwang Pharmaceutical
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine safety and efficacy of clevudine 10 mg qd for 24 weeks after completion of 24-week treatment with clevudine 30 mg qd with 12 weeks follow-up period

Timeline

Start
2004-06
Primary completion
Completion
2006-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Clevudine Small molecule 10 mg